GlobeNewswire
-
Glass House Brands Announces Uplist to NYSE
25/06/2026 -
Vivani Medical Receives Regulatory Approval for the Initiation of SLIM-1, a Phase 1 Clinical Trial of NPM-139 Semaglutide Implant in Obesity and Chronic Weight Management
25/06/2026 -
AnaCardio´s Phase 1b/2a GOAL-HF1 study in patients with Heart Failure and Reduced Ejection Fraction (HFrEF) published in The Lancet
25/06/2026 -
Herantis appoints experienced drug development expert Dr Juha Savola as Chief Medical Officer
25/06/2026 -
Atea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
25/06/2026 -
Psychedelic Science 2027 Speaker Submission Invites the Field to Bridge Promise and Practice
25/06/2026 -
Helus Pharma™ Announces Closing of US$50 Million Underwritten Offering
25/06/2026 -
Ernexa Therapeutics Launches CEO Corner to Provide Deeper Insights into Company Progress, Scientific Strategy and Vision for Patients
25/06/2026 -
The LaVie Institute Introduces Less-Invasive Breast Augmentation Technique with Rapid Recovery
25/06/2026 -
New PerfectServe Research: 85% of Healthcare Leaders Want to Switch Their Contact Center Vendors, But Most Feel Trapped
25/06/2026 -
Daré Bioscience Highlights Revenue Opportunity as CEO Discusses Upcoming Launch of Flora Sync LF5™ in Virtual Investor “What This Means” Segment
25/06/2026 -
Survey Exposes a Crisis of Avoidance in Family Caregiving
25/06/2026 -
Wandercraft Names National Seating & Mobility the Exclusive CRT Distribution Partner for Eve™ Personal Exoskeleton
25/06/2026 -
Canadian Red Cross and Walmart Canada launch annual giving campaign
25/06/2026 -
Leads Biolabs Announces Partner Oblenio Bio’s $62 Million Oversubscribed Series B Financing to Advance Tri-Specific T-Cell Engager LBL‑051 for Autoimmune Diseases into Clinical Development
25/06/2026 -
ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement
25/06/2026 -
ProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Validation of the Axiomer RNA Editing Platform
25/06/2026 -
Oblenio Bio Closes $62 Million Series B to Advance Tri-specific T-Cell Engager LBL-051 for Autoimmune Diseases into Clinical Development
25/06/2026 -
BrewDog Inverurie Reopens with New Community Champions Model
25/06/2026
Pages